Eribulin mesylate was developed as a potent microtubule-targeting cytotoxic agent to treat taxane-resistant cancers, but recent clinical trials have shown that it eventually fails in many patient subpopulations for unclear reasons. To investigate its resistance mechanisms, we developed a fluorescent analog of eribulin with pharmacokinetic (PK) properties and cytotoxic activity across a human cell line panel that are sufficiently similar to the parent drug to study its cellular PK and tissue distribution. Using intravital imaging and automated tracking of cellular dynamics, we found that resistance to eribulin and the fluorescent analog depended directly on the multidrug resistance protein 1 (MDR1). Intravital imaging allowed for real-time analysis of in vivo PK in tumors that were engineered to be spatially heterogeneous for taxane resistance, whereby an MDR1-mApple fusion protein distinguished resistant cells fluorescently. In vivo, MDR1-mediated drug efflux and the three-dimensional tumor vascular architecture were discovered to be critical determinants of drug accumulation in tumor cells. We furthermore show that standard intravenous administration of a third-generation MDR1 inhibitor, HM30181, failed to rescue drug accumulation; however, the same MDR1 inhibitor encapsulated within a nanoparticle delivery system reversed the multidrug-resistant phenotype and potentiated the eribulin effect in vitro and in vivo in mice. Our work demonstrates that in vivo assessment of cellular PK of an anticancer drug is a powerful strategy for elucidating mechanisms of drug resistance in heterogeneous tumors and evaluating strategies to overcome this resistance.
INTRODUCTION
Paclitaxel (Taxol and Abraxane) and docetaxel (Taxotere) have become front-line therapies for a variety of metastatic cancers especially of breast, ovarian, and prostate cancer origin. Unfortunately, many patients eventually develop resistance, and simple dose escalation is not an option given ensuing toxicities. These cancers become refractory to a broad spectrum of structurally unrelated compounds. Resistance to such microtubule inhibitors is complex and likely involves both pharmacokinetic (PK) effects and down-regulation of apoptosis pathways. The best-characterized resistance mechanism in cell culture is increased drug efflux mediated by the multidrug resistance protein 1 (MDR1), also known as P-glycoprotein, although the clinical relevance of this mechanism has yet to be firmly established (1) (2) (3) (4) (5) (6) .
Eribulin mesylate (Halaven) is an emerging microtubule inhibitor that is U.S. Food and Drug Administration-approved for advanced metastatic breast cancers that have been heavily pretreated with at least a taxane and anthracycline (7) . Treatment with eribulin led to increased median overall survival in certain patient subgroups compared to the physician's treatment of choice in phase 3 clinical trials (13.1 versus 10.6 months) (8) , including a subset of patients who had been on a drug holiday for 6 months or longer (9) . However, when assessed by an independent review, the median progression-free survival was not significant, and sustained disease control was marginal (10) . There are insufficient data about which patient subgroups might preferentially benefit from eribulin and common resistance mechanisms that might be shared between eribulin and previous therapies. This paucity of information stems in part from an inability to interrogate the in vivo distribution, cellular accumulation, and efflux of eribulin in cancer cells, either those untreated or those previously treated with taxanes. Furthermore, there is limited mechanistic in vivo knowledge regarding the optimal scenarios for eribulin treatment and how its efficacy could be potentiated.
To better understand the role of MDR1 in the clinical presentation of multidrug resistance, particularly to microtubule modulators, we set out to investigate the in vivo cellular accumulation of eribulin in heterogeneous tumors. We used a fluorescent eribulin analog to quantitate its tissue distribution and tumoral kinetics at the single-cell and population levels. We reasoned that such data could be used to elucidate the mechanism of clinical failure in certain patients. Eribulin features a free amino group at the C35 position, which can be synthetically modified without abrogating its microtubule-binding and destabilizing activities (11) . We took advantage of this fact and synthesized a fluorescent derivative based on covalent modification of the eribulin scaffold with a boron-dipyrromethene [BODIPY fluorophore (BFL) ] to directly analyze its cellular PK in multiple cancer types in vitro and in naïve and taxane-resistant tumors in vivo, distinguished by fluorescent expression of the MDR1-mApple fusion protein. Here, we show that the bioactivity and PK properties of eribulin-BFL are relevant to the parent compound, and MDR1 overexpression confers resistance to both. We hypothesized that mathematical analysis of image data sets would further shed light on key sources of heterogeneity in cellular-level drug dynamics and thus allow for investigation of other efficacy parameters, such as distance to microvessels, expression of efflux transporters, or coadministration with other drugs.
One strategy for modulating taxane resistance is cotreatment with inhibitors of the MDR1 drug efflux pump. Early clinical shortcomings of MDR1 inhibitors have largely been attributed to nonspecific action and/or nonselective distribution of inhibitor to target organs, leading to unacceptable systemic side effects (12) . Consequently, second-generation MDR1 inhibitors with lower toxicity were developed; however, most showed limited efficacy in human trials (13) . Hence, we investigated preclinically a third-generation MDR1 inhibitor, HM30181, currently in phase 1 clinical trials (14) (15) (16) . This compound is a structural analog of tariquidar and had demonstrated favorable potency (17) . When we tested this compound in vivo, we observed modest effects, which were subsequently shown to be related to inefficient tumor delivery. To overcome this, we designed a nanoparticle delivery system for enhanced tumoral delivery of the MDR1 inhibitor.
These quantitative, imaging-based studies not only elucidate the cellular kinetics of an investigational microtubule stabilizer, eribulin, in vitro and in vivo but also demonstrate how lessons learned at the single-cell level can reveal bioengineering strategies to potentiate drug effects. This platform approach to studying drug effects at the single-cell level may have broad application in understanding drug actions and mechanisms of resistance in vivo and, in turn, for designing better drugs and smarter trials.
RESULTS
Eribulin uptake and relationship to MDR1 in human cancer cells in vitro Synthesis and characterization of the eribulin-BFL conjugate are detailed in figs. S1 and S2, respectively. This analog (Fig. 1A) retained its anticancer efficacy in vitro (Fig. 1B) , and the fluorescent BFL tag did not impede cellular uptake (Fig. 1C) . Imaging studies showed that eribulin-BFL, like its parent molecule, arrested human tumor cells in mitosis and variably disassembled microtubules ( fig. S3 ), consistent with previous literature data using the unmodified drug (18, 19) . Strikingly, when the same cells express the MDR1-mApple fusion protein, the microtubule networks and cell division are protected ( fig. S3 ). Furthermore, treatment with both eribulin and eribulin-BFL led to the phenotype whereby microtubule disassembly was observed in wildtype cells, but not in MDR1-expressing cells. Thus, the cellular mechanism of action of eribulin-BFL reflected that of the parent eribulin.
Initially, we characterized drug uptake in wild-type and resistant cell populations when incubated with 50 nM eribulin-BFL. The resistant population was derived to mimic the clinical presentation of taxanerefractory tumors by overexpressing the MDR1 protein and selecting cells for survival in increasing concentrations of Taxol. Disparate phenotypes in drug accumulation were observed between these subgroups: a uniform and cytoplasmic distribution of eribulin-BFL was observed in wild-type cells, but negligible to sporadic accumulation was observed in the taxane-refractory population (Fig. 1C) . Substrate accumulation after eribulin-BFL incubation was subsequently quantified in thousands of single cells to verify that eribulin-BFL was indeed an avid substrate of MDR1, whereas the BFL fluorophore alone was not ( fig. S4 ).
To test whether these observations held true in other cancer cell lines, we analyzed variability in eribulin cytotoxicity (unlabeled parent compound) and eribulin-BFL accumulation across several human cancer types, including breast (two derived from metastases to the lungs), ovarian, pancreatic, and fibrosarcoma tumor cell lines (Fig.  2, A and B ) that differed in their sensitivities to taxanes and eribulin. Toxicity profiles were assayed by determining population cell viability in response to a 12-hour pulse of eribulin and assayed at 72 hours. Drug accumulation in 12 human cancer cell types was measured by flow cytometry and demonstrated a correlation between relative eribulin-BFL accumulation and cytotoxic efficacy [defined as the inverse of the half maximal inhibitory concentration (IC 50 ) of unlabeled eribulin] (Fig. 2C) . IC 50 values for eribulin ranged from sub-nanomolar to micromolar across the cell types (Fig. 2D) . Furthermore, there was a correlation between variability in the surviving fraction of cells after eribulin treatment (Fig. 2E ) and MDR1 expression levels (Fig. 2F ).
System to quantify eribulin PK in wild-type and resistant subpopulations in vivo We engineered a mosaic, resistant human cancer xenograft model with heterogeneous expression of the MDR1-mApple fusion protein. Expression of this fusion protein was validated by Western blot ( fig. S5 ). Patterning resistant cells in this way enabled quantification of cellular drug accumulation in wild-type and resistant MDR1-expressing cells in parallel in the same tumor environment (Fig. 3A) . This paradigm mimicked the genetic and epigenetic heterogeneity of real tumors and allowed for comparison of uptake into resistant and sensitive cells matched exactly for drug exposure. However, it excluded differential analysis of other transporters, such as MRP7/ABCC10, which does not play a role for eribulin ( fig. S6 ). All human cells were also stably transfected with a histone fused to a near-infrared fluorescent protein (H2B-iRFP) to facilitate automated cell tracking by in vivo imaging. Using this system, we demonstrated that MDR1 expression alone is sufficient to impede cellular eribulin accumulation (Fig. 3A) . Furthermore, MDR1-expressing cells were highly proliferative in the presence of the microtubulemodulating drug ( fig. S7A ) and its fluorescent derivative ( fig. S7B ) in vitro, demonstrating that MDR1 overexpression confers resistance to both.
The in vivo tumoral kinetics of the eribulin analog were then quantified in wild-type and taxane-refractory human cancer cells by longitudinally tracing its distribution in the mosaic tumor model grown in a mouse window chamber (Fig. 3A) . Time-lapse intravital microscopy was initiated before intravenous administration of the eribulin analog to capture its early dissemination from the vascular compartment. The segmentation system developed to track individual cells in vivo facilitated quantification of relative MDR1 protein expression (Fig. 3B ) and drug accumulation dynamics in single cells over the course of 3 hours (Fig. 3C ). This allowed direct comparison of eribulin-BFL PKs in wildtype and resistant human cancer cells, both at the single-cell (Fig. 4, A and B) and cell population (Fig. 4C ) levels.
At the systemic level, intravenously administered eribulin-BFL was characterized by a 52% redistribution within a 4-min half-life and a 48% clearance phase of 30 min, from normal vasculature into surrounding tissue ( fig. S8 ). In vivo cellular PKs in wild-type and resistant single cells were fit using nonlinear regression to an analytical model describing bidirectional diffusion and site-specific efflux out of the cell ( fig. S9A) . The single-cell efflux coefficient increased with a power dependence on MDR1 expression; an inverse relationship was observed between maximum cellular drug concentration and MDR1 expression level, measured fluorescently by the MDR1-mApple fusion protein ( fig. S9B ). Drug accumulation is not completely negligible in MDR1-expressing cells in part owing to in vivo imaging artifacts (weak tissue autofluorescence) and in part owing to other unidentified mechanisms of resistance.
Relative eribulin-BFL accumulation in resistant versus wild-type human cancer cells (ratio of the cell population means ± SEM) was quantified in a highly perfused tumor with a vessel in the imaging field (Fig. 4B ) and distant from detectable tumor vasculature, as determined by three-dimensional (3D) imaging stacks (Fig. 4 , B and C). Immediately after its administration, cellular drug accumulation differed between wild-type and resistant cells near to vessels, but after nonspecific washout of the unbound drug, resistant cells eventually accumulated nearly 50% less drug relative to wild-type cells in the same microenvironment. A one-phase association was used to describe the time-dependent ratio measure of resistant drug kinetics.
Conversely, in an imaging field with no detectable vessels in its proximity, eribulin-BFL accumulation in both cell populations at early time points was limited by the diffusion barrier to drug delivery. In this scenario, a one-phase decay described the ratio measure of resistant drug accumulation. The ratio measure normalizes for cellular distance from the drug source. The mean relative drug accumulation in resistant cells near to tumor vessels was greater than that far from tumor vessels at steady state (~20% enhanced drug loss far from vessel) (P = 0.051 according to a one-sided unpaired t test, assuming equal SD), suggesting that MDR1-expressing cells have an efflux advantage away from vessels. Relative eribulin-BFL concentrations at steady state were parameterized by the asymptote of the one-phase association or decay and analyzed in six independent z stacks that were longitudinally monitored in three mice.
Cellular inhibition of MDR1: in vitro and in vivo disparity
Up-regulation of MDR1 is a common cause of chemotherapy resistance, at least in animal models. Unfortunately, clinical trials examining the efficacy of MDR1 inhibitors have largely yielded negligible outcomes. To address this discrepancy, we assayed eribulin-BFL uptake and cytotoxicity when coadministered with potential MDR1 inhibitors using our mosaic, resistant cancer model ( fig. S10 ). We chose to further test a third-generation MDR1 inhibitor, HM30181 (Hanmi Pharmaceutical Co.), because of promising phase 1 data (16). Independently, HM30181 did not affect viability of the wild-type tumor cell line in vitro ( fig. S11A ). However, coadministration of HM30181 with unlabeled eribulin restored eribulin's bioactivity in MDR1-expressing, resistant HT1080 cells (Fig. 5 , A and C) and negligibly affected proliferation in wild-type tumor cell lines (Fig. 5B) . Likewise, accumulation of the eribulin-BFL analog in MDR1-expressing cells increased with HM30181 coadministration in a dose-dependent manner (Fig. 5D ). MDR1-expressing cells incubated with 50 nM eribulin-BFL for 1 hour did not accumulate drug in the absence of HM30181. However, co-incubation with 250 nM HM30181 allowed for drug uptake (Fig. 5E) . The resistant tumor model was then subcutaneously implanted in the dorsal skinfold window chamber of nu/nu mice to assess reversal of MDR1-mediated drug efflux (that is, eribulin-BFL accumulation) by the inhibitor in vivo. To directly test the pharmacological effects of the inhibitor itself, HM30181 was topically applied to the tumor surface by removing the window chamber coverslip. Topical delivery of HM30181 restored eribulin-BFL accumulation in resistant cells (Fig. 6A ) and significantly increased relative drug accumulation in the resistant subpopulation of single cells (Fig. 6B) . A threefold increase in eribulin-BFL accumulation was observed in resistant cell subpopulations expressing MDR1 with topical coadministration of HM30181, evaluated in three mice (Fig. 6C) . This was less than the absolute fold increase observed in resistant subpopulations in vitro (Fig. 5D ), in part owing to the detection limits and low levels of tissue autofluorescence observed in vivo, but nonetheless indicating that inhibitor activity in vivo was not a limiting factor.
Subsequently, inhibitor efficacy was assayed when intravenously coadministered with drug. HM30181 was not very water-soluble at physiological pH (7.4), and repeat dosing at 10 mg/kg (using different cosolvent formulations such as solutol and PEG-400) was observed to be poorly tolerated in mice (sickly-looking animals). Despite repeated injection of the solubilized HM30181, no reversal of MDR1-mediated drug efflux was detectable by imaging (intravenous delivery of inhibitor, Fig. 7) , which was discordant with its activity observed in vitro (Fig. 5 and fig. S10 ). Therefore, delivery was likely the factor limiting MDR1 inhibitor efficacy.
Therapeutic strategy for reversing MDR1-mediated drug resistance in vivo To solve delivery issues and to slowly release MDR1 inhibitor into tumors over time, we encapsulated HM30181 into 76 ± 7 nm (average particle size weighted by volume ± SD across six synthesis batches) poly(D,L-lactic-coglycolic acid)-b-poly(ethylene glycol) (PLGA-PEG) copolymer nanoparticles with a polydispersity index of 0.28 ± 0.05 (SD across six synthesis batches) (Fig. 7A) . A similar approach has been established for other drugs, and we therefore followed the published protocols for nanoparticle precipitation, filtering, concentration, and characterization (20, 21) . The particles were labeled with a BODIPY dye that emits in the nearinfrared channel (PLGA-B630). The MDR1 inhibitor was nanoencapsulated with an average efficiency of~30%, and for each batch, drug loading was characterized by absorbance using a standard curve.
The half-life of MDR1 inhibitor release in saline at 37°C was between 9 and 10 hours; the majority of inhibitor was released after 48 hours (Fig. 7B) . No toxicity was observed for the carrier itself ( fig. S11A ), and enhanced killing was observed in resistant cells when the inhibitor was delivered via nanoparticles as compared to standard solutionphase vehicles ( fig. S11B ). The circulatory half-life of the nanoencapsulated MDR1 inhibitor in mice was nearly 2 hours, as determined by PLGA-B630 fluorescence in multiple tumor vessels in vivo (Fig. 7C) . However, the nanoparticles maintained localization in host cells (endothelial cells and tumor-associated macrophages) and tumor cells at 24 and 48 hours ( fig. S11C ).
Nanoparticles were intravenously administered daily for 1 week (HM30181, 11 mg/kg) followed by a single intravenous dose of eribulin-BFL (3.8 mg/ml) in nu/nu mice (n = 3). With this strategy, eribulin-BFL accumulation was restored in >60% of resistant cells in vivo (Fig. 7, D and E) . For comparison, <10% of resistant cells accumulated eribulin-BFL when pretreated with nonencapsulated inhibitor or no inhibitor (Fig. 7, D and E) . Single-cell variability in inhibitor response likely reflects heterogeneity in the tissue distribution of nanoparticles and the tumor microenvironment (distance from microvasculature).
DISCUSSION
Eribulin mesylate is a potent microtubuletargeting agent but has demonstrated limited efficacy in subgroups of patients with metastatic cancer. Although it was developed to treat taxane-refractory disease, it shares a potential resistance mechanism with taxanes via MDR1-mediated drug efflux. However, the role of MDR1 in eribulin resistance has not been systematically evaluated in the context of heterogeneous tumors. Here, we synthesized a fluorescent eribulin analog (eribulin-BFL) with anticancer efficacy and PK properties comparable to its parent compound to quantitatively investigate its in vivo PK, at the single-cell level, in a resistant human cancer model characterized by heterogeneous expression of the MDR1 protein. Single-cell resolution is fundamental to understanding altered PK in multidrug-resistant tumors, which are hypothesized to clonally expand from a rare subset of cells selected under therapeutic pressure because of some fitness advantage (22) .
Intravital imaging of eribulin-BFL transport in mice enabled PK comparison between these functionally divergent subpopulations matched exactly for drug exposure. Drug uptake, efflux, and retention were analyzed in individual cells as a function of MDR1 expression and position relative to the vasculature. MDR1-expressing cells demonstrated reduced eribulin accumulation and a survival advantage over their wild-type counterparts. When this analysis was extended in vivo, MDR1-mediated drug efflux was enhanced at a distance from the tumor vasculature. This finding supports the body of evidence suggesting that MDR1 expression is hypoxia-responsive (23) (24) (25) (26) (27) (28) (29) and suggests that antiangiogenic therapies may intensify the resistance phenotype conferred by MDR1. Relative drug accumulation in resistant cells as compared to their wild-type counterparts (ratio of means ± SEM, n = 3 mice) in a highly vascularized tumor, with a vessel in the imaging field and distant from detectable tumor vasculature, as determined by 3D imaging stack. Population PK near (<200 mm) and far (>200 mm) from vessels are displayed in the image insets from representative mice. (C) Relative eribulin-BFL accumulation in MDR1-expressing cells at steady state was quantified by the fit plateau of a one-phase association (near to vessels) or decay (far from vessels). Data are mean ratios ± SEM, as well as individual animals (n = 6 independent time lapse z stacks acquired in three mice). P value determined by a one-tailed t test assuming equal SD.
The failure of many MDR1 inhibitors to clinically translate (30) has not yet been systematically evaluated in vivo at the single-cell level. Here, mathematical modeling of imaging data was used to explore the modulation of MDR1-mediated efflux dynamics, with the purpose of not only understanding PK variability but also investigating new therapeutic strategies in resistant cancer cells. We show that delivery was the main factor limiting efficacy of an MDR1 inhibitor, HM30181, in vivo, which may help explain its current limitations in the clinic, as well as the clinical failure of many of its structural analogs (30) .
To solve the in vivo delivery issue and potentiate eribulin efficacy in resistant tumors, we engineered a nanoparticle system to encapsulate the MDR1 inhibitor. Particles demonstrated sustained localization in both host and tumor cells, enhancing tissue retention and biodegradation of nanoparticles. The nanoparticles enhanced the efficacy of the MDR1 inhibitor, conceivably by reducing off-target toxicities, such as dose-limiting toxicity at blood-brain barrier (31), while increasing inhibitor-loading concentrations in the tumor. Owing to poor aqueous solubility, most MDR1 inhibitors have been administered orally as salts. This strategy has been shown to increase the systemic bioavailability, but not the tumorspecific accumulation, of drug (16), likely owing to high endogenous P-glycoprotein expression in the gut. Our nanoparticle-based delivery system was administered intravenously to bypass MDR1 inhibitor buildup in the gut to improve its systemic availability and, consequently, overall tumor exposure. The developed particle size (<100 nm) has demonstrated a PK advantage, exploiting vessel permeability while avoiding rapid renal clearance and immune cell phagocytosis (32, 33) . This nanoencapsulation strategy is one example of improving P-glycoprotein inhibitor bioavailability and tumor-specific uptake, which may readily translate to coadministration with other common therapies that are known to be P-glycoprotein substrates (taxanes and anthracyclines). Clinical translation of the encapsulated inhibitor to human applications will require advanced tolerability studies in mice and subsequently humans. Our studies highlight two alternative approaches for imaging drug PK and the power of orthogonally visualizing the therapeutic activity coadministered agents. Eribulin was detected using a fluorescent analog, eribulin-BFL, which is a direct drug-fluorophore conjugate. It is important for this strategy that the analog matches the parent as closely as possible in terms of bioactivity and PK properties. An advantage of this strategy, which was critical for our study, is that the drug itself can be visualized within single cells, thereby allowing quantitation of cellular retention in different sites in the tumor. A disadvantage is that the analog is not itself the clinical molecule, so critical comparison to the real drug is essential in all assays where that is possible. In our case, the critical property of MDR1 substrate efflux was common to the analog and the parent. With this analog, we demonstrate microtubule disassembly and mitotic arrest consistent with previous literature on unmodified eribulin (18, 19) .
Alternatively, the nanoencapsulated MDR1 inhibitor was visualized using a different color fluorophore (BODIPY-630) that was coassembled into the nanoparticle delivery system. This has the advantage that the effect of the clinical molecule was tested directly and the disadvantage that cellular binding and accumulation could not be assayed explicitly. However, tagging the particle was sufficient to quantify tumor uptake and location and will be valuable for rational design of nanoparticle size and chemistry in ongoing studies. Concurrent analysis of the tumoral distribution of both the nanoencapsulated inhibitor and therapeutic substrate whose cellular retention it was promoting further enhanced PK optimization of the dual-administered therapies.
Multiple pathways have been implicated in cellular multidrug resistance, including altered drug metabolism, down-regulation of apoptotic pathways, and transformed DNA damage repair; our study was limited to just one critical pathway in the development of multidrug resistance: drug efflux. As a primary model system, we used two nearly isogenic human cell lines, differing only by fluorescent MDR1 expression. The strength of this design is that observed differences in drug interactions between the cell populations are predominantly attributable to MDR1 expression, independent of other transporters that may be expressed in all cell populations. Its limitation is that it excludes other transporters that may be relevant to clinical multidrug resistance. Overall, the system enabled specific analysis of MDR1-mediated effects in the context of an uncontrolled and heterogeneous tumor microenvironment. A valuable extension of this work will be systematic quantification of transformed cell pharmacodynamics in response to the altered PK observed in multidrug resistance using fluorescent reporters for apoptosis and DNA damage repair.
These quantitative PK studies provoked development of a nanoparticle delivery platform for controlling multidrug resistance that could also be applied to other primary cytotoxic therapies where emerging resistance is the ultimate cause of drug failure. This mechanistic strategy has the potential to control intrinsic or acquired multidrug resistance observed in late-stage refractory patients, particularly after persistent exposure to well-established cytotoxic therapies like taxanes. Its discovery, through systematic analysis of fluorescent drug retention in functionally divergent cell populations, underscores the utility of this quantitative method for investigating cellular drug resistance and evaluating new strategies to overcome such resistance, particularly when PK mechanisms are implicated.
MATERIALS AND METHODS

Study design
The objective of this study was to investigate and quantify the cellular PK of a fluorescent eribulin analog (eribulin-BFL) in a tumor model that is spatially heterogeneous for taxane resistance. This model enabled direct comparison of eribulin-BFL transport in functionally divergent subpopulations in vivo, matched for drug and environmental exposures. We systematically analyzed its PK at both the single-cell and cell population levels with a focus on understanding mechanisms of its resistance and for evaluating strategies to overcome that resistance. All in vitro studies were performed in triplicate, unless otherwise specified. All in vivo mouse imaging experiments were performed with three mice per treatment group, unless otherwise specified, and hundreds of single cells were analyzed per mouse (unblinded). In each mouse, multiple areas of tumors were imaged as 3D stacks and as a function of time allowing analysis of thousands of cells per experiment. The study endpoints (drug distribution over 5 t 1/2 or intracellular drug concentration) were predetermined by the scientific questions. Female mice were randomly chosen for tumor implantations. All data are shown, and outliers were not excluded.
Synthesis of eribulin-BFL
Synthesis of eribulin-BFL was carried out as described in fig. S1A and Supplementary Methods.
Synthesis of HM30181
HM30181, N-{2-(2-{4-(2-{6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl}-4-oxo-4H-chromene-2-carboxamide, was synthesized as described previously (34, 35) . Characterization data agree with those reported in the literature (34): 56 (s, 1H), 4.06 (s, 3H), 4.04 (s, 3H), 3.87 (s, 3H), 3.86 (s, 3H) 
Human cell lines
All cell lines were from the American Type Culture Collection, unless otherwise stated. MDA-MB-231 and MDA-MB-436 (human triplenegative breast adenocarcinomas), A2780 and OVCAR-429 (human ovarian cancers, gifts from M. Birrer, Massachusetts General Hospital), and TC-71 (human Ewing's sarcoma) cells were maintained at 37°C, 5% CO 2 , and 100% relative humidity in RPMI medium supplemented with 10% fetal bovine serum, 100 IU of penicillin, streptomycin (100 mg/ml), and 2 mM L-glutamine. SK-BR3 (human breast adenocarcinoma), 1834 and 4175 (human breast metastases to the lung, gift from J. Massagué, Memorial Sloan Kettering Cancer Center), PANC1 (human pancreatic cancer), and HT1080 (human fibrosarcoma) cells were maintained at 37°C, 5% CO 2 , and 100% relative humidity in minimum essential medium supplemented with 10% fetal bovine serum, 100 IU of penicillin, streptomycin (100 mg/ml), and 2 mM L-glutamine.
To specifically visualize MDR1-mediated PK effects, an HT1080 cell line expressing an MDR1-mApple fluorescent fusion protein was constructed using components of the MDR1 expression plasmid [Addgene, plasmid no. 10957: pHaMDRwt (36)] and a lentiviral vector pLVX (Clontech) expressing H2B-mApple (37) as described in Supplementary Methods. HT1080 cells, including those expressing MDR1-mApple, were further labeled with a histone H2B-iRFP fusion protein for in vivo nuclear tracking. MRP7/ABCC10-transfected and vehicle-transfected human embryonic kidney 293 cells were provided by E. Hopper to assay the relevance of this transporter to eribulin-BFL PK (38) . MRP7/ABCC10 expression was validated by Western blot ( fig. S11A ).
Window chamber model
All animal experiments were carried out in accordance with guidelines from the Institutional Subcommittee on Research Animal Care. Female nude mice aged 6 to 8 weeks (Cox7, Massachusetts General Hospital) were implanted with a dorsal skin window chamber (Fig. 3A) . About 1 × 10 6 HT1080 cells with mixed expression of MDR1-mApple (1:1) were harvested in up to 50 ml of phosphate-buffered saline (PBS) and injected under the fascia. Tumors were grown for 2 to 4 weeks before imaging, such that they became vascularized and reached several millimeters in size.
In vitro cytotoxicity assays Cell viability assays were performed in a 96-well format; cells were seeded at 2500 cells per well in 200 ml of Dulbecco's modified Eagle's medium without antibiotic selection 24 hours before application of eribulin, different MDR1 inhibitors, HM30181, verapamil (SigmaAldrich, V4629), sulfinpyrazone (Sigma-Aldrich, S9509), imatinib (Selleck Chem, S1026), ponatinib (Selleck Chem, S1490), or the nanoparticle delivery platform. The next day, increasing concentrations of unlabeled and labeled eribulin were dissolved in dimethyl sulfoxide (DMSO) and added to each well, while maintaining a final DMSO concentration less than 0.25%. When investigating whether MDR1 inhibitors can be used to potentiate eribulin's cytotoxic effects, serial dilutions of inhibitor were also added to the cells. The drug/inhibitor-containing medium was washed out of the cells after a 16-to 24-hour exposure, and cell viability was assayed 72 hours later. When comparing nonencapsulated and nanoencapsulated HM30181 profiles, the inhibitor (10 mM HM30181 stock in DMSO) and nanoencapsulated inhibitor (6.4 mM HM30181 in deionized H 2 O; determined by the method described above) were diluted to 1.3 mM in medium and then serially diluted 1:2 until reaching a final concentration of 5 nM. In the case of the nonencapsulated inhibitor, the DMSO content was normalized to a final concentration of 0.013%. The cells were incubated with the varying concentrations of inhibitor (100 nM to 5 mM) for 6 hours, and then eribulin (10 mM stock in DMSO) was applied to designated wells (at a final assay concentration of 25 nM); wells designated for treatment with inhibitor only were normalized with additional DMSO. After incubating for 24 hours, the medium was replaced with medium without drug/inhibitor, and the cells were incubated for an additional 48 hours. Cell viability was quantified using the PrestoBlue Cell Viability Reagent (Life Technologies) and using a Tecan Safire 2 plate reader. Fluorescence measurements were normalized to cells exposed to a DMSO control (no drug/inhibitor), drug concentrations were logtransformed, and parameters were estimated by nonlinear regression of the normalized fluorescence measures to the Hill equation or a sigmoidal dose response (for assays investigating inhibitory effects of HM30181) using Prism 6.0. All measurements were repeated in triplicate and are presented as means ± SEM.
Nanoformulation of HM30181
Fresh nanoparticle batches were prepared in overnight reactions for experiments the following day. HM30181 (3.6 mg) and PLGA-B630 (4 mg) were added to PLGA-PEG (20 mg) in a final solution of 50:50 acetonitrile/N,N-dimethylformamide. After mixing, the solution was slowly added dropwise to deionized H 2 O (40 ml) being stirred at 800 rpm. After overnight stirring, the solution was filtered through a 0.45-mm pore size cellulose acetate syringe filter (Fisher Scientific) and washed with deionized H 2 O using Amicon Ultra (Millipore) 100-kD molecular weight cutoff (MWCO) centrifuge filters spun at 3000g. Nanoparticle size distributions were immediately characterized by dynamic light scattering (Zetasizer APS, Malvern). For each batch, drug loading was characterized by absorbance at 400 nm, with a five-point standard curve (R 2 > 0.99) using purified HM30181, while compensating for BODIPY-630 absorbance using a standard curve that measured both fluorescence [excitation/emission (ex/em), 630/690 nm] and absorbance (400 nm) of purified PLGA-BODIPY-630.
For measurement of HM30181 release from PLGA-PEG nanoparticle encapsulation, nanoparticles were resuspended in PBS (300 ml) at 37°C. At each time point measurement, the solution was filtered using 100-kD MWCO centrifuge filters (Millipore) and spun at 3000g for 15 min. Concentrated nanoparticles were resuspended in fresh PBS to a volume of 300 ml and kept at 37°C until the next time point measurement. The filtrate was resuspended to a final volume of 200 ml of PBS, and the drug concentration was measured by absorbance as described above.
For independent analysis of nanoparticle circulation, a separate batch of nanoparticles labeled with a BODIPY emitting in the green channel were prepared by conjugating 10-(2-aminoethyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-dipyrrolo{1,2-c:2′,1′-f}{1,3,2}diazaborinin-4-ium-5-uide hydrochloride [synthesized by adapting a known method (39) ] to PLGA using the methods described for the case of the PLGA-BODIPY-630. Loadings were determined as described above (ex/em, 483/525 nm).
Intravital microscopic imaging
All imaging experiments were carried out in accordance with guidelines from the Institutional Subcommittee on Research Animal Care. When tumors became vascularized and reached several millimeters in size, intravital imaging was performed (40, 41) . Mice were anesthetized with 2% isofluorane in oxygen (2 liters min −1 ) on a heated microscope stage, and the lateral tail vein was cannulated for intravenous administration of eribulin-BFL, the MDR1 inhibitor, and/or a 500-kD amino-dextran labeled with Pacific Blue N-hydroxysuccinimide ester (Invitrogen), according to the manufacturer's instructions. The dextran was first used to identify vascularized regions within the tumor, whereas fluorescent reporters of wild-type and resistant cancer cells were used to identify regions of interest (all cells were identified by the H2B-iRFP fusion protein, whereas the resistant subset was identified by the MDR1-mApple fusion protein). Serial images and z stacks were acquired in representative areas of the tumor, and eribulin-BFL was injected during acquisition of the timelapse imaging series. The drug was formulated by dissolving 7.5 ml of 10 mM solution in DMSO along with 30 ml of 1:1 N,N-dimethylacetamide/ solutol solution. PBS (112.5 ml) was then slowly added with sonication to obtain a final injection volume of 150 ml. When evaluating the cellular effect of intravenously administering the MDR1 inhibitor, a solution (10 mg/kg) of inhibitor in N,N-dimethylacetamide/solutol solution was either co-injected with eribulin or preinjected within 24 hours and up to three times before eribulin administration. For topical application of drug and inhibitor, 16 ml of 10 mM HM30181 was dissolved in 800 ml of PBS along with 0.5 ml of 10 mM eribulin-BFL solution in DMSO and applied directly to the tumor surface. For topical application of drug alone, 16 ml of DMSO was dissolved in 800 ml of PBS along with 0.5 ml of 10 mM eribulin-BFL solution in DMSO and applied directly to the tumor surface. For nanoparticle delivery of the MDR1 inhibitor, particles were intravenously injected daily for 1 week (~11 mg/kg, 1:1 in PBS), with a secondary dose administered on the first and last day (days 1 and 5). After inhibitor loading, the eribulin-BFL solution (previously described) was intravenously injected and imaged in the mosaic tumor model at steady state (>20 min after administration).
Static and time series images were collected using a customized Olympus FV1000 confocal microscope (Olympus America). An XLUMPLFLN 20× water immersion objective (numerical aperture 1.0, Olympus America) was used for data collection typically with 2× to 4× zoom, thereby assessing 30 to 200 cells per imaging FOV. The vascular probes, eribulin-BFL, MDR1-mApple, H2B-iRFP, and at times HM30181 nanoparticle, were scanned and excited sequentially using 405-, 473-, 559-, and 633-nm diode lasers, respectively. Emitted fluorescence was separated using dichroic beam splitters SDM473, SDM560, and SDM640 in combination with band-pass filters BA430-455, BA490-540, BA575-620, and/or BA655-755 (Olympus America). Confocal imaging settings were optimized for each fluorophore to prevent photobleaching, phototoxicity, and crosstalk between channels.
Image analysis
To account for depth fluctuations in the imaging plane, frames from sequential z stacks were co-registered by maximizing the mutual information between consecutive imaging stacks. To scale up our single-cell observations to the population level, algorithms for automated segmentation and tracking of in vivo cellular dynamics were then developed on the basis of a coupled active contours model (34) . Individual cells were seeded in this algorithm according to the centroid of each histone, semiautomatically identified by a local maxima finder. Each contour was iteratively updated according to the histone region curvature, gradient, energy, and repulsion from adjacent contours, enabling segmentation of densely clustered nuclei. The segmented nuclei were then morphologically dilated to encompass the cell cytoplasmic compartment. We used phantom data to directly correlate the fluorescence signal with drug concentrations, as described previously (35) . Thereby, the cellular concentration of eribulin was mapped over time as a function of MDR1 expression level. Drug concentration curves were background-subtracted. If necessary when evaluating static images, manual segmentation algorithms were implemented to precisely segment individual cells at lower magnification settings. When evaluating the percentage of MDR1-expressing cells accumulating drug as a function of MDR1 inhibitor delivery method, the cellular frequency of MDR1-expressing cells with a drug concentration within 1.96 SD of the mean native cell drug concentration imaged simultaneously was reported. All image analysis was performed using MATLAB (MATLAB and Statistics Toolbox Release 2013b, The MathWorks Inc.).
Mathematical model of cellular drug efflux
Time-dependent cellular drug concentration profiles were exported from MATLAB into Prism 6.0 (GraphPad) for nonlinear determination of optimized PK parameters. The weighted imaging half-life of the eribulin-BFL was measured in normal vessels of the mouse ear and was fit to a two-phase exponential decay. Cellular eribulin-BFL PKs were fit using nonlinear regression to an analytical model describing bidirectional diffusion and site-specific efflux out of the cell.
Statistical analysis
Distributions were analyzed using Prism 6.0 software and are presented as means ± SEM. Comparisons of two groups were performed using unpaired t tests or for more than two groups by applying one-way ANOVA using the Tukey multiple comparison test. Differences were considered significant at P < 0.05. Two-sided P values were uniformly calculated unless otherwise specified.
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